What Was Approved?
On July 14, 2026, the U.S. Food and Drug Administration approved Revtorpyk (gedatolisib) in combination with fulvestrant, with or without palbociclib, for certain adults with advanced breast cancer.
The approval applies to adults with:
- Hormone receptor-positive (HR-positive) breast cancer
- HER2-negative breast cancer
- Locally advanced or metastatic disease
- No detected PIK3CA mutation
- Disease progression during or after at least one line of endocrine therapy in the metastatic setting
The specific eligibility requirements are important because Revtorpyk is not approved for every patient with HR-positive or HER2-negative breast cancer.
What Is Revtorpyk?
Revtorpyk contains gedatolisib, a targeted cancer therapy.
It is used together with fulvestrant and may also be combined with palbociclib, depending on the treatment plan.
FDA lists Revtorpyk among its 2026 novel drug approvals, meaning gedatolisib had not previously been approved in the United States.
What Does HR-Positive, HER2-Negative Mean?
Breast cancers can be classified according to biological characteristics of the tumor.
HR-positive means the cancer cells have receptors for hormones such as estrogen or progesterone that can contribute to tumor growth.
HER2-negative means the tumor does not meet criteria for HER2-positive disease.
These characteristics help clinicians select treatments that target specific pathways involved in the cancer.
Why Does PIK3CA Mutation Status Matter?
The FDA-approved indication for Revtorpyk specifically applies when a PIK3CA mutation has not been detected.
Testing for tumor biomarkers can therefore be an important part of determining whether this treatment is appropriate.
Patients should not assume that the medicine is appropriate based only on having HR-positive/HER2-negative breast cancer.
How Is Revtorpyk Given?
The FDA-recommended dose of gedatolisib is:
180 mg by intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 28-day treatment cycle.
It is given in combination with fulvestrant, with or without palbociclib.
Treatment generally continues until the cancer progresses or unacceptable toxicity occurs.
Dosing instructions for fulvestrant and palbociclib should be followed separately according to their prescribing information.
What Did the Clinical Trial Show?
The approval was supported by VIKTORIA-1, an open-label, randomized, multicenter clinical trial involving 392 adults with locally advanced or metastatic HR-positive, HER2-negative breast cancer.
Participants were assigned to one of three groups:
- Gedatolisib plus fulvestrant and palbociclib
- Gedatolisib plus fulvestrant
- Fulvestrant alone
The main effectiveness measure was progression-free survival, or PFS, which measures how long patients lived without the cancer getting worse.
How Much Did Progression-Free Survival Improve?
For patients receiving gedatolisib plus fulvestrant and palbociclib, median progression-free survival was 9.3 months, compared with 2.0 months for patients receiving fulvestrant alone.
For patients receiving gedatolisib plus fulvestrant without palbociclib, median progression-free survival was 7.4 months, compared with 2.0 months with fulvestrant alone.
Both comparisons showed statistically significant improvements in progression-free survival.
What About Tumor Response?
Among patients with measurable disease, the objective response rate was:
- 32% with gedatolisib, fulvestrant, and palbociclib
- 28% with gedatolisib and fulvestrant
- 1% with fulvestrant alone
These results describe outcomes observed in the clinical trial and do not predict how an individual patient will respond.
Did the Study Show an Overall Survival Benefit?
Overall survival data were not mature at the time of the FDA progression-free survival analysis.
At that point, approximately 25% of patients in the overall study population had died.
For that reason, it would be premature to conclude from this approval that Revtorpyk has demonstrated a specific overall survival benefit.
What Are the Important Safety Warnings?
The FDA prescribing information includes warnings and precautions involving several potentially important adverse effects.
Stomatitis
Revtorpyk can cause stomatitis, which refers to inflammation or sores in the mouth.
Patients should report significant mouth pain, ulcers, or difficulty eating or drinking to their healthcare team.
Dermatologic Reactions
Skin-related adverse reactions can occur.
New or worsening rash or other significant skin changes should be discussed with the treating clinician.
Hyperglycemia
Revtorpyk can cause hyperglycemia, or elevated blood glucose.
Patients may require blood glucose monitoring during treatment, particularly if they already have diabetes or other risk factors.
Embryo-Fetal Toxicity
Based on its mechanism and available information, Revtorpyk may cause fetal harm when administered during pregnancy.
Patients who are pregnant or could become pregnant should discuss pregnancy and contraception recommendations with their oncology team.
Does Revtorpyk Work for Every Advanced Breast Cancer?
No.
This approval applies to a specifically defined group of patients.
Treatment selection may depend on:
- Hormone receptor status
- HER2 status
- PIK3CA mutation status
- Previous endocrine treatments
- Extent of disease
- Other medications
- Overall medical condition
Treatment decisions should be made by an oncology team familiar with the patient’s complete medical history.
Why Is This Approval Important?
HR-positive/HER2-negative breast cancer can eventually become resistant to endocrine treatment.
Revtorpyk provides another targeted treatment option for certain patients whose disease has progressed after endocrine therapy in the metastatic setting.
The clinical study showed a significant improvement in progression-free survival compared with fulvestrant alone in the population studied.
Bottom Line
Revtorpyk (gedatolisib) is a newly FDA-approved treatment used with fulvestrant, with or without palbociclib, for certain adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a detected PIK3CA mutation.
In the VIKTORIA-1 study, Revtorpyk-containing regimens significantly improved progression-free survival compared with fulvestrant alone.
Because the treatment can cause important adverse effects and is approved only for a specific patient population, treatment requires appropriate cancer biomarker testing, oncology supervision, and ongoing monitoring.
Sources
- U.S. Food and Drug Administration (FDA) — FDA Approves Gedatolisib With Fulvestrant, With or Without Palbociclib, for HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer, July 14, 2026.
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2026.
- U.S. Food and Drug Administration (FDA) — Revtorpyk Approval Letter, July 14, 2026.